Targeted retinoblastoma management: when to use intravenous,... : Current Opinion in
Ophthalmology Targeted retinoblastoma management: when to use intravenous, intra-arterial …

The management of retinoblastoma has gradually changed over the past 10 years. Over
95% of children with retinoblastoma in the United States are cured with modern techniques …

PURPOSE: To evaluate the reliability of the International Classification of Retinoblastoma
(ICRB) for predicting treatment success with chemoreduction (CRD). DESIGN …

Background We previously developed a reliable and valid method for classifying the
intensity of pediatric cancer treatment. The Intensity of Treatment Rating Scale (ITR‐2.0) 1 …

The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone
marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated …

Background Analysis of 52 eyes with high-risk retinoblastoma managed with
postenucleation adjuvant chemotherapy using vincristine sulfate, etoposide phosphate, and …

Background To evaluate the occurrence of second malignant neoplasms (SMN) following
chemoreduction (CRD) with carboplatin, vincristine, and etoposide (CEV) as frontline …

Purpose: To determine the efficacy of primary intravenous chemotherapy (IVC) plus
secondary intraarterial chemotherapy (IAC) for patients with advanced retinoblastoma …

Purpose The objective of this study was to compare outcomes after intravenous
chemotherapy (IVC) versus intra-arterial chemotherapy (IAC) for unilateral retinoblastoma …

Objective To evaluate retinoblastoma regression patterns following chemoreduction and
adjuvant therapy. Participants A total of 557 retinoblastomas. Methods A retrospective …